---
title: "Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294783340.md"
description: "A precision oncology company, Evexta Bio S.A., established by Truffle Capital, known for founding Abivax and Carvolix, revealed a clinical partnership and supply deal aimed at commencing a Phase 1b trial. The study will couple their primary investigational compound, rupitasertib, with Roche's investigational compound giredestrant, an SERD, focusing on treating ER+, HER2-, ESR1-m patients. This collaboration marks a significant step in the development of targeted therapies."
datetime: "2026-08-04T07:02:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294783340.md)
  - [en](https://longbridge.com/en/news/294783340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294783340.md)
---

# Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer

A precision oncology company, Evexta Bio S.A., established by Truffle Capital, known for founding Abivax and Carvolix, revealed a clinical partnership and supply deal aimed at commencing a Phase 1b trial. The study will couple their primary investigational compound, rupitasertib, with Roche's investigational compound giredestrant, an SERD, focusing on treating ER+, HER2-, ESR1-m patients. This collaboration marks a significant step in the development of targeted therapies.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings Narratives](https://longbridge.com/en/news/293799255.md)
- [Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billion](https://longbridge.com/en/news/293380197.md)
- [Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894](https://longbridge.com/en/news/295525767.md)
- [United Therapeutics CEO Chair Martine Rothblatt disposes of 9,500 shares for $4.81 million](https://longbridge.com/en/news/295974899.md)
- [Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295850563.md)